China's Epilepsy Market Growing Rapidly; Attracting More Multinational Companies
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - The Chinese anti-epilepsy drug market is expected to grow at an annual rate of roughly 30 percent in coming years, and multinational companies account for most of that market share, healthcare analysts predict
You may also be interested in...
NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).